Abstracts tagged "rheumatoid arthritis (RA) and rituximab"

Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Eun Young Lee⁸, Francisco G. Medina-Rodriguez⁹, Pavel Shesternya¹⁰, Sebastiao Radominski¹¹, Dong Hyuk Sheen¹², Mie Jin Lim¹³, Jung-Yoon Choe¹⁴, Leysan Myasoutova¹⁵, Taek Kwon¹⁶, Sang Joon Lee¹⁶, Seung-Cheol Shim¹⁷ and Chang-Hee Suh¹⁸, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁹Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹⁰Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹¹CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹²Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁴Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ¹⁵City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁶CELLTRION, Inc., Incheon, South Korea, ¹⁷Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ¹⁸Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
Abstract Number: 1502 • 2014 ACR/ARHP Annual Meeting
A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis
Jean-Claude P. Becker¹, Donghua Yin², Lisa Ann Melia³, Ruifeng Li⁴, Barry Gumbiner⁵, Dolca Thomas⁶, George Spencer-Green⁷ and Xu Meng², ¹Pfizer Biosimilars Research and Development/Medical Affairs., Pfizer Inc., New York, NY, ²Clinical Pharmacology/Pharmacometrics, Pfizer Inc., San Diego, CA, ³Biotechnology Clinical Development, Pfizer Inc., San Diego, CA, ⁴Biostatistics, Pfizer Inc., Cambridge, MA, ⁵Worldwide Research and Development, Pfizer Inc., San Diego, CA, ⁶Biosimilars Research and Development Unit, Pfizer Inc., New York, NY, ⁷Worldwide Research and Development, Pfizer Inc., Cambridge, MA
Background/Purpose: PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar physicochemical and in vitro functional properties. This…
Abstract Number: 1419 • 2014 ACR/ARHP Annual Meeting
Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience
Sandra Chartrand^1,2, Jeffery J. Swigris³, Lina Peykova² and Aryeh Fischer⁴, ¹Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, ²Rheumatology, National Jewish Health, Denver, CO, ³Autoimmune Lung Center, National Jewish Health, Denver, CO, ⁴Rheumatology / ILD Program, National Jewish Health, Denver, CO
Background/Purpose: Small series have suggested that rituximab (RTX) may be effective as rescue-therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We sought to describe…
Abstract Number: 991 • 2014 ACR/ARHP Annual Meeting
The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis
Cecile Gamonet¹, Marina Deschamps², Sandrine Marion³, Philippe Saas⁴, Gilles Chioccha³, Christophe Ferrand⁴ and Eric Toussirot^5,6, ¹INSERM UMR1098, Etablissement Français du Sang / Université de Franche Comté, Besançon, France, ²INSERM UMR1098 / Etablissement Français du Sang/ Université de Franche Comté, Besançon, France, ³Chronic Inflammation and Immune System Labex Inflamex, Université Versailles Saint Quentin, Montigny le Bretonneux, France, ⁴Etablisement Français du Sang ; Université de Franche Comté, INSERM UMR1098, Besançon, France, ⁵Clinical Investigation Centre Biotheraoy CIC 1431, Rheumatology Department, Univesity Hospital, besancon, France, ⁶Rheumatology, University hospital, Besançon, France
Background/Purpose: the identification of predictive factors for the response, or alternatively factors for resistance to biological agents is a relevant goal in the management of…
Abstract Number: 500 • 2013 ACR/ARHP Annual Meeting
Fixed Versus On-Flare Retreatment With Rituximab In RA – Results From The Cererra Collaboration
Katerina Chatzidionysiou¹, Elisabeth Lie², Evgeny Nasonov³, Galina Lukina³, Merete Lund Hetland⁴, Ulrik Tarp⁵, Karel Pavelka⁶, Cem Gabay⁷, Dan Nordström⁸, Helena Canhao⁹, Matija Tomsic¹⁰, Piet van Riel¹¹, Juan Gomez-Reino¹², Ioan Ancuta¹³, Tore Kvien¹⁴ and Ronald van Vollenhoven¹⁵, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³ARBITER, Institute of Rheumatology, Moscow, Russia, ⁴DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ⁸ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ⁹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ¹⁰Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, ¹¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹²Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹³Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ¹⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose: The data on how to optimally retreat patients with RA with rituximab (RTX) have been limited so far. The aim of this analysis was…
Abstract Number: 432 • 2013 ACR/ARHP Annual Meeting
Use Of Rituximab As Second Line Biologic Agent Compared With Adalimumab, Etanercept and Infliximab In Patients With Rheumatoid Arthritis. a Report From The Rhumadata® Clinical Database and Registry
Louis Bessette¹, Denis Choquette², Diane Sauvageau³, Boulos Haraoui⁴, Jean Pierre Pelletier², Jean-Pierre Raynauld³, Edith Villeneuve³ and Louis Coupal², ¹Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁴Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…
Abstract Number: 419 • 2013 ACR/ARHP Annual Meeting
A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Yukiko Kamogawa¹, Kyohei Nakamura², Ryu Watanabe², Tsuyoshi Shirai¹, Yoko Fujita³, Yuko Shirota⁴, Noriko Fukuhara¹, Hiroshi Fujii², Shinichiro Saito⁵, Tomonori Ishii² and Hideo Harigae², ¹Tohoku University, Sendai, Japan, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁴Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of hematology and rheumatology, Tohoku University, Sendai, Japan
Background/Purpose: Methotrexate (MTX) has been increasingly administered by patients with rheumatoid arthritis (RA). In rare cases, we experience development of malignant lymphoma in patients treated…
Abstract Number: 2376 • 2013 ACR/ARHP Annual Meeting
A Novel and Effective Prediction Model Of Response To Rituximab In Rheumatoid Arthritis
Alper M. van Sijl¹, Michel W.P. Tsang-A-Sjoe¹, Hennie G. Raterman¹, Michael T. Nurmohamed² and Alexandre E. Voskuyl³, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²VU University Medical Center, Amsterdam, Netherlands, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: For patients with rheumatoid arthritis (RA) who are refractory to tumor necrosis factor (TNF)-inhibitors, it is still not clear which determinants are associated with…
Abstract Number: 1736 • 2013 ACR/ARHP Annual Meeting
A Randomized, Controlled, Multicenter, 2‑Arm, Parallel‑Group, Double-Blind Study To Demonstrate The Equivalence Of CT-P10 To Innovator Rituximab With Respect To Pharmacokinetic Profile In Patients With Rheumatoid Arthritis
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Jan Brzezicki⁸, Eun Young Lee⁹, Francisco G. Medina-Rodriguez¹⁰, Pavel Shesternya¹¹, Sebastiao Radominski¹², Marina Stanislav¹³, Volodymyr Kovalenko¹⁴, Dong Hyuk Sheen¹⁵, Mie Jin Lim¹⁶, Jung-Yoon Choe¹⁷, Sung Young Lee¹⁸, Seung-Cheol Shim¹⁹ and Chang-Hee Suh²⁰, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Clinic of Rheumatology and Connective Tissue Diseases University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Torun, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Wojewodzki Szpital Zespolony Oddzial Reumatologiczny, Elblag, Poland, ⁹Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ¹⁰Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹¹Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹²CETI Centro de Estudos em Terapias Inovadoras Ltda, Curitiba, Brazil, ¹³Central Russian National Institute of Rheumatology, Russian Academy of Medical Science, Moscow, Russia, ¹⁴Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁵Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹⁶Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁷Rheumatology, Daegu Catholic University Medical Center, Daegu, South Korea, ¹⁸Clinical Planning and Medical Affairs Department, CELLTRION, Inc., Incheon, South Korea, ¹⁹Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ²⁰Department of Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose: CT-P10 was developed as a biosimilar candidate to innovator rituximab (RTX), an anti-CD20 monoclonal antibody. This trial is a phase I study to demonstrate…
Abstract Number: 1438 • 2013 ACR/ARHP Annual Meeting
Comparative Effectiveness Of Rituximab Vs. Subsequent Anti-Tumor Necrosis Factor In Patients With Rheumatoid Arthritis With Prior Exposure To TNFi
Leslie R. Harrold¹, George W. Reed², Robert P. Magner¹, Ashwini Shewade³, Ani John³, Jeffrey D. Greenberg⁴ and Joel M. Kremer⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²CORRONA, Inc., Southborough, MA, ³Genentech Inc., South San Francisco, CA, ⁴NYU Hospital for Joint Diseases, New York, NY, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: In patients (pts) who have failed 1 or more TNF-α inhibitors (TNFi), there is little data to guide clinical decision making in terms of…
Abstract Number: 1004 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Two Rituximab Based Therapeutic Regimens For Longstanding Rheumatoid Arthritis
Luca Quartuccio¹, Rossella Di Bidino², Matteo Ruggeri³, Domenico Biasi⁴, Franco Schiavon⁵, Leonardo Punzi⁶, Silvano Adami⁷, Americo Cicchetti³ and Salvatore De Vita⁸, ¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ²HTA Unit, “A.Gemelli” Teaching Hospital, Rome, Italy, ³Faculty of Economics, Catholic University of the Sacred Heart, Rome, Italy, ⁴Rheumatology Clinic, University of Verona, Verona, Italy, ⁵Rheumatology Clinic, University of Padova, Padova, Italy, ⁶University of Padova, Rheumatology Unit, Padova, Italy, ⁷Rheumatology Department, University of Verona, Verona, Italy, ⁸Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: socioeconomic costs of rheumatoid arthritis (RA) are very high. Biologic therapies with different biologic targets are now available for moderate to severe RA, and…
Abstract Number: 958 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients
Tamarah D. de Jong¹, Saskia Vosslamber¹, Wilco de Jager², Hennie G. Raterman³, Alexandre E. Voskuyl⁴, Kyra A. Gelderman¹ and Cornelis L. Verweij⁵, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Although rituximab therapy is successful in the majority of rheumatoid arthritis (RA) patients, 30-40% of patients do not respond. The mechanism behind this is…
Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting
The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis
Lucía Silva-Fernández^1,2, Mark Lunt³, Audrey S. Low², Kath D. Watson³, BSRBR Control Centre Consortium², Deborah P. Symmons², Kimme L. Hyrich⁴ and On behalf of the BSRBR⁵, ¹Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ²Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁵British Society for Rheumatology, London, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
Abstract Number: 498 • 2013 ACR/ARHP Annual Meeting
A Systematic Review and Meta-Analysis Comparing Low- Versus High-Dose Rituximab For Rheumatoid Arthritis
Markus Bredemeier, Fernando K. de Oliveira and Claúdia M. Rocha, Rheumatology, Hospital Nossa Senhora da Conceição - Grupo Hospitalar Conceição, Porto Alegre, Brazil
Background/Purpose: The approved dose of rituximab (RTX) for rheumatoid arthritis (RA) is 2x1000 mg infusions given 2 weeks apart. There is contradictory evidence regarding the…
Abstract Number: 496 • 2013 ACR/ARHP Annual Meeting
Effectiveness Of Repeated Courses Of Rituximab In RA – Results From The Cererra Collaboration
Katerina Chatzidionysiou¹, Elisabeth Lie², Evgeny Nasonov³, Galina Lukina³, Merete Lund Hetland⁴, Ulrik Tarp⁵, Karel Pavelka⁶, Cem Gabay⁷, Dan Nordström⁸, Helena Canhao⁹, Matija Tomsic¹⁰, Piet van Riel¹¹, Juan Gomez-Reino¹², Ioan Ancuta¹³, Tore Kvien² and Ronald van Vollenhoven¹⁴, ¹Dept of Medicine, Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³ARBITER, Institute of Rheumatology, Moscow, Russia, ⁴DANBIO, Department of Rheumatology, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, ⁸ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, ⁹Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Instituto de Medicina Molecular, Rheumatology Research Unit, Rheumatology Research Unit, on behalf of the Rheumatic Diseases Portuguese Register, Lisbon, Portugal, ¹⁰Department of Rheumatology, BioRx.si, University Medical Centre Ljubjana, Ljubljana, Slovenia, ¹¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹²Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ¹³Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, ¹⁴Unit for Clinical Research Therapy. Inflammatory Diseases (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose: Retreatment with rituximab (RTX) is common clinical practice, although several aspects regarding retreatment, such as frequency, need to be further elucidated. The aim of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.